[Therapeutic management of nonvalvular atrial fibrillation]

M A Gunawardene1,2,3, J Hartmann4,5,6, M Jularic4,5,6

  • 1Klinik für Kardiologie, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099, Hamburg, Deutschland. M.gunawardene@asklepios.com.

Herz
|July 8, 2020
PubMed

Insights

Atrial fibrillation (AF) management involves risk stratification for oral anticoagulation (OAC) or left atrial appendage closure. Rhythm control strategies, including catheter ablation (CA), aim to improve quality of life for symptomatic patients.

Area of Science:

  • Cardiology
  • Cardiac Electrophysiology

Background:

  • Atrial fibrillation (AF) is a common cardiac arrhythmia linked to higher mortality.
  • Effective, individualized patient treatment is crucial.

Purpose of the Study:

  • To outline current management strategies for atrial fibrillation.
  • To discuss risk stratification and treatment options including anticoagulation, device implantation, and catheter ablation.

Main Methods:

  • Risk stratification to determine oral anticoagulation (OAC) needs.
  • Consideration of left atrial appendage closure devices for specific patient groups.
  • Rhythm control strategies, including catheter ablation (CA), for symptomatic AF.

Main Results:

  • OAC is initiated based on stroke risk.
  • Left atrial appendage closure is an alternative for patients with OAC contraindications.
  • Catheter ablation (pulmonary vein isolation) shows high success rates for AF freedom (70-80% paroxysmal, 50% persistent) at 1 year.
  • CA survival advantage is currently limited to heart failure patients.

Conclusions:

  • AF management requires tailored treatment based on risk assessment.
  • Catheter ablation is a key rhythm control strategy, primarily for symptomatic relief and quality of life improvement, with proven survival benefits in heart failure patients.

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
284
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
241
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
159
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
179
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
104
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
334